End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Steven Pipe, Wolfgang Miesbach, Michael Recht, Frank Leebeek, Nigel Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra LeQuellec, Sean Gill, Vaibhav Mahajan, Douglass Drelich, Paul Monahan
Institutions: University of Michigan, University Hospital Frankfurt, Yale University, Erasmus MC, University of North Carolina at Chapel Hill, Azienda Ospedaliero-Universitaria Careggi, Oregon Health & Science University, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, University of Amsterdam, CSL (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417010241
Cites:
Cited by:
Related to: